Across TCGA pan-cancer cohorts, DNAJC9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DNAJC9 data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher DNAJC9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DNAJC9 expression acts as an unfavorable survival marker.

ACC, CESC, and CHOL are the cancer types where DNAJC9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.188	0.820	<.001	12	view →
CESC	OS	Median	All	0.091	0.585	.029	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: DNAJC9 tumor-vs-normal RNA expression · all DNAJC9 data types